Cue Biopharma, Inc.·4

Jul 25, 4:49 PM ET

Seidel Ronald D. III 4

4 · Cue Biopharma, Inc. · Filed Jul 25, 2018

Insider Transaction Report

Form 4
Period: 2018-07-23
Seidel Ronald D. III
EVP, Head of R&D
Transactions
  • Award

    Stock Option (right to buy)

    2018-07-23+75,00075,000 total
    Exercise: $11.54Exp: 2025-07-23Common Stock (75,000 underlying)
Footnotes (1)
  • [F1]This stock option grant becomes exercisable in eight semi-annual installments beginning July 23, 2018.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION